| Name | Title | Contact Details |
|---|
MedAptus is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InterPro is a leading global provider of business process outsourcing services. We deliver transcription services, contact center solutions, document management, enterprise portal development, employer services, medical revenue lifecycle support, and
Watercrest Senior Living Group specializes in the development and operations of assisted living and memory care communities, market repositioning and advisory services. The principals have an impressive track record of leading the turnaround of underperforming assets and the stabilization of newly built communities. Partnering with a wide variety of stakeholders such as land owners, real estate developers, investors, financial institutions, and REITs, Watercrest Senior Living Group focuses on its core strengths, operations management of assisted living and memory care communities and the development of servant leaders. With state of the art information systems and key vendor partnerships, we are well positioned to efficiently assimilate both existing assisted living and memory care communities and the next generation of senior living product.
Bramalea Denistry is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.